Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cellipont, Secretome Partner for cGMP Manufacturing of STM-01 Cellular Therapy | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Cellipont, Secretome Partner for cGMP Manufacturing of STM-01 Cellular Therapy

Cellipont to provide technology transfer, analytical method transfer, and cGMP manufacturing for the STM-01 Master Cell Bank.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Cellipont Bioservices, a cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), have entered a partnership for cGMP manufacturing of Secretome Therapeutic’s lead asset STM-01.

Under this partnership, Cellipont Bioservices will provide technology transfer, analytical method transfer, and cGMP manufacturing for the STM-01 Master Cell Bank.

STM-01 is a novel cellular therapy designed to address severe cardiovascular diseases, particularly dilated cardiomyopathy (DCM) and heart failure with preserved ejection fraction (HFpEF). Two multiple-ascending dose Phase 1 clinical trials studying STM-01 in patients with heart failure are expected to begin in the first quarter of 2025.

“This partnership with Secretome Therapeutics represents an exciting opportunity for Cellipont to support the advancement of cutting-edge cell therapies,” said Darren Head, CEO of Cellipont Bioservices. “We are very excited to collaborate with a company so dedicated to developing innovative solutions that address significant unmet medical needs and improve patient outcomes.”

“A key objective for Secretome in 2025 is to produce STM-01 drug product that is suitable for late-stage clinical testing and potential commercial use,” said Vinny Jindal, President and CEO of Secretome Therapeutics. “Cellipont’s world-class facility and deep expertise in cGMP manufacturing for cell and gene therapies make them an ideal manufacturing partner and align perfectly with our mission to deliver transformative therapies for cardiovascular diseases and beyond.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics